Spanos W J, Perez C A, Marcus S, Poulter C A, Doggett R L, Steinfeld A D, Grigsby P W
University of Louisville School of Medicine, KY.
Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):399-403. doi: 10.1016/0360-3016(93)90059-5.
From August 1985 through September 1989, 284 patients with advanced pelvic malignancies were entered into a trial (RTOG 8502) of palliative split course radiation (4440 cGy in three courses of 1480 cGy/2 days/4 fractions with a rest of 2-4 weeks between courses). The initial 148 patients were part of a Phase II acceptable response rate and minimal acute or late toxicity (IJRBP 17:659-662, 1989). The present analysis is a report of the subsequent 136 patients randomized between rest intervals of 2 weeks versus 4 weeks to determine if length of rest would influence tumor response or patient toxicity. The patients were stratified for performance status (Karnofsky Performance Status) and histology. The patients were evenly matched for age and sex. There was a trend toward increased acute toxicity incidence in patients with shorter rest interval (5/68 versus 0/68; p = .07). Late toxicity was not significantly different between the two groups. Decreasing the interval between courses did not result in a significant improvement in tumor response (CR+PR = 34% vs. 26%, p = n.s.). More patients in the 2 week groups completed all three courses (72% vs. 63%). Not surprisingly, patients completing cell three courses had a significantly higher overall response rate than for patients completing less than three courses (42% vs. 5%) and higher complete response rate (17% vs. 1%). A multivariate analysis indicated performance status as the significant predictor for number of courses completed. For Karnofsky Performance Status greater than or equal to 80, the survival at 12 months was 40% for the 2 week interval and 25% for the 4 week interval. Performance status and histology were the only significant variables in a multivariate analysis of survival.
从1985年8月至1989年9月,284例晚期盆腔恶性肿瘤患者进入一项姑息性分割疗程放疗试验(RTOG 8502)(三个疗程共4440厘戈瑞,每个疗程1480厘戈瑞,分2天给予,每天4次分割,疗程间休息2至4周)。最初的148例患者为II期试验的一部分,其可接受的缓解率以及最小的急性或晚期毒性反应(《国际放射肿瘤学、生物学、物理学杂志》17:659 - 662, 1989)。本分析报告了随后的136例患者,这些患者被随机分为休息间隔为2周和4周两组,以确定休息时间长短是否会影响肿瘤反应或患者毒性。患者根据体能状态(卡诺夫斯基体能状态评分)和组织学进行分层。患者在年龄和性别方面匹配良好。休息间隔较短的患者急性毒性发生率有升高趋势(5/68对0/68;p = 0.07)。两组间晚期毒性无显著差异。缩短疗程间隔并未使肿瘤反应得到显著改善(完全缓解 + 部分缓解 = 34%对26%,p = 无统计学意义)。2周组完成所有三个疗程的患者更多(72%对63%)。不出所料,完成三个疗程的患者总体缓解率显著高于完成少于三个疗程的患者(42%对5%),完全缓解率也更高(17%对1%)。多因素分析表明体能状态是完成疗程数的显著预测因素。对于卡诺夫斯基体能状态评分大于或等于80的患者,2周间隔组12个月生存率为40%,4周间隔组为25%。在生存的多因素分析中,体能状态和组织学是仅有的显著变量。